Literature DB >> 15571800

Specificity of interphase fluorescence in situ hybridization for detection of chromosome aberrations in tumor pathology.

M G Tibiletti1.   

Abstract

Interphase fluorescence in situ hybridization (IFISH) is an interesting and intriguing cytogenetic approach in the study of tumor chromosomal abnormalities when metaphases are not available. This technique can be applied to different types of tumor nuclei, including imprinted nuclei (IM), nuclei obtained from conventional cytogenetic procedures (PB), frozen nuclei, paraffin-embedded nuclei (PE), and nuclei extracted from paraffin-embedded sections (EX). IFISH is a high-sensitivity approach in tumor studies that can give evidence of genetic aberrations present in a small percentage of cells that are likely to escape detection if only molecular techniques are applied. Despite its high sensitivity and versatility, IFISH is an indirect cytogenetic method and needs controls to have adequate specificity. This study includes present data obtained in IFISH experiments using different types of probes (alpha-satellite and YAC clones) hybridized on different types of normal control nuclei, such as PB, IM, EX, and PE nuclei, to define the threshold level for monosomy and trisomy of different chromosomal regions. My findings demonstrate that the cut-off values depend both on the types of probes and on the types of target nuclei. Therefore, even if IFISH is a versatile, high-sensitivity technique for detecting chromosomal abnormalities, the lack of accurate controls may result in the misdiagnosis of some abnormalities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15571800     DOI: 10.1016/j.cancergencyto.2004.03.005

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs).

Authors:  Yijun Ruan; Hong Sain Ooi; Siew Woh Choo; Kuo Ping Chiu; Xiao Dong Zhao; K G Srinivasan; Fei Yao; Chiou Yu Choo; Jun Liu; Pramila Ariyaratne; Wilson G W Bin; Vladimir A Kuznetsov; Atif Shahab; Wing-Kin Sung; Guillaume Bourque; Nallasivam Palanisamy; Chia-Lin Wei
Journal:  Genome Res       Date:  2007-06       Impact factor: 9.043

2.  Clinical findings and HER-2/neu gene amplification status of breast carcinoma patients.

Authors:  Feride Iffet Sahin; Zerrin Yilmaz; Mahmut Can Yagmurdur; Fatma Belgin Atac; Binnaz Handan Ozdemir; Hamdi Karakayali; Beyhan Demirhan; Mehmet Haberal
Journal:  Pathol Oncol Res       Date:  2006-12-25       Impact factor: 3.201

Review 3.  Primary small cell neuroendocrine carcinoma of the kidney: morphological, immunohistochemical, ultrastructural, and cytogenetic study of a case and review of the literature.

Authors:  Stefano La Rosa; Barbara Bernasconi; Donata Micello; Giovanna Finzi; Carlo Capella
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

4.  FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.

Authors:  Catherine T-S Chung; Gilda Da Cunha Santos; David M Hwang; Olga Ludkovski; Melania Pintilie; Jeremy A Squire; Ming-Sound Tsao
Journal:  J Clin Pathol       Date:  2010-07       Impact factor: 3.411

5.  Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.

Authors:  Satoshi Ichikawa; Noriko Fukuhara; Hiroki Katsushima; Taro Takahashi; Joji Yamamoto; Hisayuki Yokoyama; Osamu Sasaki; Osamu Fukuhara; Jun Nomura; Kenichi Ishizawa; Ryo Ichinohasama; Akihiko Muto; Kazuhiko Igarashi; Hideo Harigae
Journal:  Cancer Sci       Date:  2014-03-08       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.